Lombard appoints new money man
This article was originally published in Clinica
Endovascular stent graft specialist Lombard Medical has appointed William Kullback chief financial officer. Mr Kullback has over 30 years’ corporate finance and accounting experience, including more than 20 years in CFO roles in both large publicly-traded and privately held companies. He replaces Ian Ardill, who had been with Lombard since 2012. The personnel change comes after Lombard moved its listing from the UK’s AIM market to Nasdaq stock exchange in the US in April. The company’s flagship Aorfix endovascular stent graft for treating abdominal aortic aneurysms is both US FDA-approved and CE-marked.